MX9800760A - Metodos para el tratamiento del asma alergica. - Google Patents

Metodos para el tratamiento del asma alergica.

Info

Publication number
MX9800760A
MX9800760A MX9800760A MX9800760A MX9800760A MX 9800760 A MX9800760 A MX 9800760A MX 9800760 A MX9800760 A MX 9800760A MX 9800760 A MX9800760 A MX 9800760A MX 9800760 A MX9800760 A MX 9800760A
Authority
MX
Mexico
Prior art keywords
treatment
methods
allergic asthma
ige
antagonists
Prior art date
Application number
MX9800760A
Other languages
English (en)
Other versions
MXPA98000760A (es
Inventor
Robert B Fick Jr
Paula M Jardieu
Monika B Schoenhoff
Steven J Shire
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24021032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9800760(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MXPA98000760A publication Critical patent/MXPA98000760A/es
Publication of MX9800760A publication Critical patent/MX9800760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen métodos de tratamiento de asma alérgica con antagonistas de IgE, incluyendo anticuerpos anti-IgE, variantes de IgE, antagonistas de péptido, moléculas peptidomiméticas y otras pequeñas.
MX9800760A 1995-07-27 1996-07-24 Metodos para el tratamiento del asma alergica. MX9800760A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US08/508,014 1995-07-27
PCT/US1996/012275 WO1997004807A1 (en) 1995-07-27 1996-07-24 Methods for treatment of allergic asthma

Publications (2)

Publication Number Publication Date
MXPA98000760A MXPA98000760A (es) 1998-04-01
MX9800760A true MX9800760A (es) 1998-04-30

Family

ID=24021032

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800760A MX9800760A (es) 1995-07-27 1996-07-24 Metodos para el tratamiento del asma alergica.

Country Status (16)

Country Link
EP (1) EP0841946B2 (es)
JP (1) JP4153560B2 (es)
CN (2) CN101172099B (es)
AR (1) AR003468A1 (es)
AT (1) ATE225185T1 (es)
AU (1) AU715338B2 (es)
CA (1) CA2226624C (es)
DE (1) DE69624116T3 (es)
DK (1) DK0841946T4 (es)
ES (1) ES2186796T5 (es)
IL (1) IL122733A (es)
MX (1) MX9800760A (es)
PT (1) PT841946E (es)
RU (1) RU2229288C2 (es)
WO (1) WO1997004807A1 (es)
ZA (2) ZA966075B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP2116265B1 (en) * 2000-10-12 2020-12-23 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102006009437A1 (de) * 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
AU2008211807B2 (en) * 2007-01-29 2013-09-19 Valtion Teknillinen Tutkimuskeskus Method for producing novel IgE based reagents
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
ES2427890T3 (es) * 2007-12-21 2013-11-04 Cangene Corporation Formulaciones estabilizadas de factor IX que contienen trehalosa
UA101487C2 (en) * 2007-12-21 2013-04-10 Ф. Хоффманн-Ля Рош Аг Humanized b-ly1 antibody formulation
CN102272154A (zh) 2008-10-29 2011-12-07 惠氏有限责任公司 单域抗原结合性分子的纯化方法
CN104740631B (zh) * 2008-10-29 2019-04-16 阿布林克斯公司 单域抗原结合性分子的制剂
SI2512450T1 (en) 2009-12-15 2018-05-31 Ascendis Pharma Endocrinology Division A/S A dry growth hormone composition transiently bound to a polymeric carrier
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
CN102533704A (zh) * 2010-12-30 2012-07-04 上海雅心生物技术有限公司 即配即用型的胰蛋白酶制剂
LT2691112T (lt) * 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
US9089529B2 (en) * 2011-10-25 2015-07-28 Prothena Therapeutics Limited Antibody formulations and methods
KR102276304B1 (ko) 2013-09-27 2021-07-14 한미약품 주식회사 지속형 인간 성장 호르몬 제제
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
WO2019019998A1 (zh) 2017-07-25 2019-01-31 江苏恒瑞医药股份有限公司 一种il-15蛋白复合物药物组合物及其用途
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
CA3185192A1 (en) 2020-07-10 2022-01-13 Sujun DENG Anti-ige engineered antibody and application thereof
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
DE122006000007I2 (de) * 1987-12-31 2008-03-27 Tanox Inc -tragenden b-lymphocyten befinden.
WO1993019197A1 (en) * 1992-03-20 1993-09-30 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
JPH07118168A (ja) * 1993-10-19 1995-05-09 Tomoyasu Ra ＩｇＥ産生抑制剤
ATE264388T1 (de) * 1992-09-24 2004-04-15 Tanox Biosystems Inc Umgestaltete monoklonale antikörper gegen ein immunglobulinisotyp
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
DE69624116T2 (de) 2003-06-18
JPH11510172A (ja) 1999-09-07
CA2226624C (en) 2013-07-16
DK0841946T3 (da) 2003-02-10
WO1997004807A1 (en) 1997-02-13
ZA966075B (en) 1998-01-19
EP0841946A1 (en) 1998-05-20
ES2186796T5 (es) 2009-04-01
CN101172099B (zh) 2012-02-15
AR003468A1 (es) 1998-08-05
CA2226624A1 (en) 1997-02-13
CN101172099A (zh) 2008-05-07
ATE225185T1 (de) 2002-10-15
RU2229288C2 (ru) 2004-05-27
EP0841946B1 (en) 2002-10-02
ZA966240B (en) 1998-01-23
DK0841946T4 (da) 2009-02-16
CN101172100A (zh) 2008-05-07
DE69624116D1 (de) 2002-11-07
JP4153560B2 (ja) 2008-09-24
DE69624116T3 (de) 2009-07-09
IL122733A (en) 2001-09-13
AU715338B2 (en) 2000-01-20
IL122733A0 (en) 1998-08-16
AU6638196A (en) 1997-02-26
EP0841946B2 (en) 2008-10-15
PT841946E (pt) 2003-02-28
ES2186796T3 (es) 2003-05-16

Similar Documents

Publication Publication Date Title
MX9800760A (es) Metodos para el tratamiento del asma alergica.
HUP9900422A3 (en) Novel protein and methods for the production of the same
WO1994016094A3 (en) Recombinant anti-vla4 antibody molecules
CA2220169A1 (en) Improved methods for the manufacture of magnetically responsive particles
AU5665696A (en) Novel methods for the assay of troponin i and t and complexe s of troponin i and t and selection of antibodies for use in immunoassays
ZA92617B (en) Method of immobilizing and crosslinking proteins and other molecules and uses thereof.
HK1027833A1 (en) Improved anti-ige antibodies and methods of improving antibodies
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
DE69625516D1 (de) Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
EP0870826A4 (en) NEW PROTEINS AND MONOCLONAL ANTIBODIES AGAINST THESE
DE68903576D1 (de) Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen.
TR199600315A2 (tr) Kararli sivi süspansiyonlar ve bunlari inceleme yöntemi.
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
ITMI951764A0 (it) Peptide sintetasi ingegnerizzate e loro impiego per la produzione via non-ribosomale di peptidi
AU9222698A (en) Novel molecules of the tnfr-ligand-related protein family and uses thereof
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
AU5301196A (en) Method for stimulating an immune response
ATE214803T1 (de) Stabilisierte standards und kalibratoren
AU3498795A (en) Method of blocking the sec receptor
EP1452542A3 (en) Reshaped human monoclonal antibodies specific for IgE
AU3749499A (en) Novel molecules of the bgckr-related protein family and uses thereof
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
CA2152166A1 (fr) Detection de la mucoviscidose ou d'une mutation du gene cftr
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum

Legal Events

Date Code Title Description
FG Grant or registration